CytomX Therapeutics Inc [CTMX] stock is trading at $1.00, down -0.99%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
CytomX Therapeutics Inc [NASDAQ: CTMX] stock has seen the most recent analyst activity on May 28, 2024, when Piper Sandler upgraded its rating to a Overweight and also boosted its price target to $3.50 from $2.25. Previously, Wedbush upgraded its rating to Outperform on May 09, 2024, and kept the price target unchanged to $8. On May 06, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $8 on the stock. JP Morgan upgraded its rating to a Neutral. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $2.60 on November 14, 2022. Wedbush downgraded its rating to Neutral for this stock on July 07, 2022, and downed its price target to $2. In a note dated July 07, 2022, Piper Sandler downgraded an Neutral rating on this stock and revised its target price from $10 to $1.50.
CytomX Therapeutics Inc [CTMX] stock has fluctuated between $0.98 and $5.85 over the past year. Currently, Wall Street analysts expect the stock to reach $5.73 within the next 12 months. CytomX Therapeutics Inc [NASDAQ: CTMX] shares were valued at $1.00 at the most recent close of the market. An investor can expect a potential return of 473.0% based on the average CTMX price forecast.
Analyzing the CTMX fundamentals
CytomX Therapeutics Inc [NASDAQ:CTMX] reported sales of 126.62M for the trailing twelve months, which represents a growth of 26.71%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at 0.05%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.11%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is -0.41 and Total Capital is 0.34. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.45.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9800 points at the first support level, and at 0.9600 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0300, and for the 2nd resistance point, it is at 1.0600.
Ratios To Look Out For
For context, CytomX Therapeutics Inc’s Current Ratio is 1.04. In addition, the Quick Ratio stands at 1.04 and the Cash Ratio stands at 0.34. Considering the valuation of this stock, the price to sales ratio is 0.62 and price to earnings (TTM) ratio is 5.89.
Transactions by insiders
Recent insider trading involved Landau Jeffrey B, Chief Business Officer, that happened on Aug 20 ’24 when 4181.0 shares were sold. SVP, Chief Scientific Officer, BELVIN MARCIA completed a deal on Aug 20 ’24 to sell 4181.0 shares. Meanwhile, General Counsel ROWLAND LLOYD A sold 4181.0 shares on Aug 20 ’24.
